Covid-19 drug Molnupiravir in India


COVID-19 treatment drug Molnupiravir under in is for the treatment of adult patients with COVID-19, conditions, a press release from the city-based drugmaker said.

Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Singapore, a subsidiary of Merck & Co. Producer, and supplied Molnupiravir to over 100 low and middle-income countries, including India.

Vice-Chairman and Managing Director Aurobindo said, that we are delighted with the timely permission from DCGI for the licensed version of Molnupiravir as it opens up access to a treatment for patients

And enable us to help battle the pandemic with effective and high-quality pharmaceutical products.

The licensed version of Molnupiravir, Aurobindo enjoys backward integration with in-house active pharmaceutical ingredient manufacturing which equips it with stronger control on the Quality systems and Supply chain.

Product is made at the Company’s producing facilities in India that are approved by global regulatory agencies including USFDA and UK MHRA.

The firm Kamladityya Construction Pvt Ltd had won the bid to construct the vice president enclave. Hospitals have begun prescribing Covid antiviral drug molnupiravir citing benefits of the drug outweigh the potential risks it may have for high-risk patients.

The company has adequate capacities to meet the global demand across the over 100 LMI Countries for the product, Aurobindo told, we have to remember that this drug has major safety concerns.

It can cause teratogenicity, mutagenicity and it can also cause cartilage damage and can also be damaging to muscles, Dr. Bhargava told a media briefing, PTI reported.

Contraception will have to be done for three months for males and females if this drug is given because the child born could be problematic due to teratogenic influence.

The ICMR chief said the United States has approved it based on only 1,433 patients in which a three percent reduction was observed in symptoms in patients with mild disease.

It is not a national treatment protocol for Covid, Dr. Bhargava’s opinion we have concerns about the drug and its use during lactation, in children, soft-tissue injuries, reproductive age group,” he said, adding that they have debated on its usage twice and will further debate over it.”

Follow and connect with us on Facebook, LinkedIn & Twitter